Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference
Neos Therapeutics, a pharmaceutical company focused on central nervous system products, announced that CEO Jerry McLaughlin will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 3:40 p.m. ET. The event will be accessible via a live webcast on the company's Investor Relations page. A replay will be available for 30 days post-event. Neos markets several ADHD treatments, including Adzenys XR-ODT and Cotempla XR-ODT, and is developing NT0502 for sialorrhea in patients with neurological conditions.
- None.
- None.
DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m. ET.
A live webcast of the fireside chat will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Following the presentation, a replay of the webcast will be available on Neos’ website for 30 days.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a commercial-stage pharmaceutical company developing and manufacturing central nervous system (CNS)-focused products. The Company markets Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD. The Company also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions. Additional information about Neos is available at www.neostx.com.
CONTACTS:
Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah.mccabe@sternir.com
FAQ
When will Neos Therapeutics participate in the Cantor Virtual Global Healthcare Conference?
How can I watch the Neos Therapeutics fireside chat?
What products does Neos Therapeutics offer for ADHD?
What is the development candidate NT0502 by Neos Therapeutics?
